Skip to content

Beam Therapeutics Inc.

BEAM· NasdaqCore metricsCIK 1745999

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -6.85%
Market cap
$2.49B
103.5M shares
Filings
515
$307.00K
Q3 2026+120.0% FY25 yoy
-$134.41M
Q3 2026N/M FY25 yoy
-$141.32M
Q3 2026N/M FY25 yoy
-$311.21M
Q3 2026derivedN/M FY25 yoy
-$1.28
Q3 2026N/M FY25 yoy
$213.27M
Q3 2026+4.6% FY25 yoy
$2.49B
—
17.0×
2.6×
-16.02%
—

Twelve months to Sep 30, 2026 · derived

Price

$24.02+6.85%+$1.54past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$139.74MFY 2025
$377.71M0FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$139,743,000reported
FY 20242024-12-31$63,518,000reported
FY 20232023-12-31$377,709,000reported
FY 20222022-12-31$60,920,000reported
FY 20212021-12-31$51,844,000reported
FY 20202020-12-31$24,000reported
FY 20192019-12-31$18,000reported

Biological products, except diagnostic substances

Beam Therapeutics Inc. is the 25th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Beam Therapeutics Inc. · CIK 1745999 · Engraved from SEC EDGAR